Vivek Jayaraman Sells 165,200 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) COO Vivek Jayaraman sold 165,200 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $274,232.00. Following the sale, the chief operating officer owned 1,747,674 shares of the company’s stock, valued at $2,901,138.84. This trade represents a 8.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Cerus Price Performance

Shares of Cerus stock opened at $1.80 on Wednesday. The stock’s fifty day moving average is $2.28 and its 200-day moving average is $1.88. The firm has a market capitalization of $345.91 million, a PE ratio of -22.50 and a beta of 1.51. The company has a quick ratio of 1.17, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. Cerus Corporation has a 12-month low of $1.12 and a 12-month high of $2.96.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The business had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%. Equities analysts anticipate that Cerus Corporation will post -0.08 earnings per share for the current year.

Institutional Investors Weigh In On Cerus

Several hedge funds have recently bought and sold shares of CERS. Caitong International Asset Management Co. Ltd grew its stake in Cerus by 321.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 46,801 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 35,692 shares in the last quarter. Invesco Ltd. lifted its position in shares of Cerus by 28.8% in the fourth quarter. Invesco Ltd. now owns 309,168 shares of the biotechnology company’s stock worth $637,000 after purchasing an additional 69,087 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Cerus by 48.6% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 53,028 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 17,336 shares during the period. Engineers Gate Manager LP boosted its holdings in shares of Cerus by 4.7% during the fourth quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 6,415 shares during the period. Finally, Kotler Kevin purchased a new position in Cerus during the fourth quarter valued at approximately $2,084,000. 78.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Zacks Research cut shares of Cerus from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 12th. Finally, TD Cowen reissued a “buy” rating on shares of Cerus in a research note on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Cerus News Summary

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Cerus named COO Vivek Jayaraman as President & Chief Executive Officer effective July 1, 2026, with current CEO William “Obi” Greenman becoming Executive Chairman — a clear, pre‑announced succession that typically reduces leadership uncertainty. Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
• Positive Sentiment: Large institutional investors have been increasing positions recently (notably AQR, UBS and Millennium), which can support liquidity and signal professional investor interest.
• Neutral Sentiment: The company disclosed executive compensation adjustments tied to the leadership change; these may be neutral-to-slightly-positive if they align incentives, but they could also increase near‑term dilution depending on grant size and vesting. Compensation Changes
• Negative Sentiment: Multiple insiders sold sizable blocks around $1.66: CEO William Greenman (~447,757 shares), incoming CEO/COO Vivek Jayaraman (~165,200), CFO Kevin Green (~127,544), Richard Benjamin (~101,740) and Chrystal Jensen (~113,008). Collective insider liquidations of this scale can create short‑term downward pressure and raise questions about timing or liquidity needs. CEO SEC Filing Benjamin SEC Filing
• Negative Sentiment: Analyst coverage is mixed-to-negative: recent downgrades (Wall Street Zen cut buy→hold; Zacks to strong sell) leave the consensus at a “Reduce” rating, which can limit upside from new buyers until sentiment improves.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.